BRIEF-Savara Announces The U.K. Medicines And Healthcare Products Regulatory Agency (Mhra) Has Accepted The Molbreevi* Marketing Authorisation Application (Maa) For Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

Savara, Inc.

SVRA

0.00

April 7 (Reuters) - Savara Inc SVRA.O:

SAVARA ANNOUNCES THE U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) HAS ACCEPTED THE MOLBREEVI* MARKETING AUTHORISATION APPLICATION (MAA) FOR AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP)
SAVARA INC - MHRA DECISION ON MOLBREEVI MAA EXPECTED IN Q4 2026
SAVARA INC - FDA PDUFA DATE FOR MOLBREEVI BLA SET FOR AUGUST 22, 2026
SAVARA INC - CHMP DECISION ON MOLBREEVI MAA EXPECTED IN Q1 2027

Source text: ID:nBw5WV8Gma

Further company coverage: SVRA.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.